首页 > 市场调查报告书 > 医疗设备

医学影像诊断

临床试验诊断影像市场规模、份额和成长分析（按服务/软体、模式、治疗领域、最终用户和地区划分）—产业预测（2026-2033 年）

市场调查报告书

商品编码

1897876

临床试验诊断影像市场规模、份额和成长分析（按服务/软体、模式、治疗领域、最终用户和地区划分）—产业预测（2026-2033 年）

Clinical Trial Imaging Market Size, Share, and Growth Analysis, By Service and Software (Service, Software), By Modality (Computed Tomography, Magnetic Resonance Imaging), By Therapeutic Area, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月17日 | 出版商:

SkyQuest | 英文 194 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，临床试验诊断影像市场规模将达到 14.2 亿美元，到 2025 年将达到 15.3 亿美元，到 2033 年将达到 28 亿美元，在预测期（2026-2033 年）内，复合年增长率为 7.82%。

临床试验影像市场预计将迎来强劲成长，这主要得益于生物技术和製药产业的扩张，这两个产业正大力投资研发标靶治疗。此外，对医学影像公司投资的增加以及将先进影像技术整合到医疗设备研究中的策略性併购也推动了这一成长。技术进步提高了临床试验影像资料的撷取、分析和呈现方式，影像分析软体具有准确性、一致性和扩充性等优势。此外，计算技术的日益普及也进一步提升了临床试验影像的程度。定量影像生物标记联盟（QIBA）已建立标准化方法，以确保可靠且统一的数据收集，有助于改善试验结果。

临床试验影像市场驱动因素

临床试验影像市场主要受製药和生物技术领域研发投入不断增长的推动。随着药物研发过程日益复杂，对用于监测临床试验期间治疗效果和疾病进展的先进影像技术的需求也日益增长。诸如磁振造影（MRI）、正子断层扫描（PET）和电脑断层扫描）等先进影像技术，能够提供关于新型治疗方法安全性和有效性的关键数据，从而促进其在科学研究中的评估。这一趋势凸显了先进影像技术在确保新型医疗方法和治疗方案成功方面所发挥的关键作用。

临床试验影像市场的限制因素

临床试验影像市场的一大障碍是先进影像技术（例如MRI、PET和电脑断层扫描）的高昂成本。这些成本显着增加了临床试验的整体预算，为中小型製药公司和研究机构取得这些关键资源带来了挑战。此外，对放射科医生和其他影像专家等专业人员的需求也为临床试验带来了额外的经济负担，并阻碍了先进影像技术在研究活动中的广泛应用。因此，这些因素限制了先进影像解决方案在临床试验中的潜在应用。

临床试验影像诊断市场趋势

临床试验影像市场的一大趋势是人工智慧 (AI) 和机器学习技术与诊断影像系统的融合日益增强。这些 AI 驱动的工具提高了影像分析的准确性和效率，显着降低了人为错误的机率，并加快了结果报告速度。透过自动化复杂的影像处理任务，AI 简化了临床诊断流程，使诊断影像解决方案更易于取得且更具成本效益。这项技术进步不仅能够实现更快、更可靠的数据解读，还有助于临床决策支持，反映出人们越来越依赖先进的诊断影像技术来优化临床试验结果。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲（MEA）
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争格局

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市集活动
主要企业市占率（2025 年）

主要企业简介

ICON plc
Medpace
Clario
IXICO plc
Resonance Health Ltd.
Radiant Sage
WCG Clinical
Medical Metrics, Inc.
Prism Clinical Imaging
Boston Imaging Core Lab
Voiant
Calyx
Biospective Inc.
Micron, Inc.
Imaging Endpoints
Perspectum
Competence Network Life Sciences（Pharmtrace）
Median Technologies
Image Core Lab
Image Analysis Group（IAG）

简介目录

Product Code: SQMIG35H2309

Clinical Trial Imaging Market size was valued at USD 1.42 Billion in 2024 and is poised to grow from USD 1.53 Billion in 2025 to USD 2.8 Billion by 2033, growing at a CAGR of 7.82% during the forecast period (2026-2033).

The clinical trial imaging market is poised for robust growth, primarily fueled by the expanding biotechnology and pharmaceutical sectors, which are significantly investing in research and development to create targeted therapies. This growth is also driven by increased investments in medical imaging companies and strategic mergers and acquisitions that integrate advanced imaging technologies for medical device investigations. Technological advancements have enhanced the collection, analysis, and presentation of clinical trial imaging data, with image analysis software providing advantages such as accuracy, consistency, and scalability. Additionally, the greater adoption of computing technologies offers further improvements in clinical trial imaging. The Quantitative Imaging Biomarker Alliance (QIBA) has established standardized methods, ensuring reliability and uniformity in data collection for enhanced trial outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Clinical Trial Imaging market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Clinical Trial Imaging Market Segments Analysis

Global Clinical Trial Imaging Market is segmented by Service and Software, Modality, Therapeutic Area, End User, and Region. Based on Service and Software, the market is segmented into Services (Operational Imaging Services, Read Analysis Services, System And Technical Support Services, Trial Design And Consulting Services), Software. Based on Modality, the market is segmented into Computed Tomography, Magnetic Resonance Imaging, Ultrasound, Positron Emission Tomography, X-Ray, Others. Based on Therapeutic Area, the market is segmented into Oncology, Infectious Diseases, Neurology, Cardiovascular System Disorders, Endocrinology, Immunological Disorders, Others. Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Medical Device Manufacturers, Contract Research Organizations, Academic And Government Research Institutes, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Clinical Trial Imaging Market

The clinical trial imaging market is significantly driven by the rising investments in research and development within the pharmaceutical and biotechnology sectors. As the process of drug development becomes increasingly complex, there is a growing demand for precise imaging technologies to monitor treatment effects and disease progression during clinical trials. Advanced imaging modalities, including MRI, PET, and CT scans, provide essential data regarding the safety and effectiveness of new therapies, facilitating their evaluation in scientific studies. This trend highlights the critical role of advanced imaging in ensuring the success of new medical treatments and therapies.

Restraints in the Clinical Trial Imaging Market

A significant barrier in the Clinical Trial Imaging market is the elevated costs associated with sophisticated imaging technologies such as MRI, PET, and CT scans. These expenses can substantially escalate the overall budget of clinical trials, posing challenges for smaller pharmaceutical companies and research institutions in accessing these crucial resources. Furthermore, the need for specialized professionals, including radiologists and other imaging experts, adds an additional layer of financial strain, deterring the widespread implementation of advanced imaging in research activities. Consequently, these factors contribute to limiting the potential application of advanced imaging solutions within clinical trials.

Market Trends of the Clinical Trial Imaging Market

A prominent trend in the clinical trial imaging market is the increasing integration of Artificial Intelligence (AI) and machine learning technologies into imaging systems. These AI-driven tools enhance the accuracy and efficiency of image analysis, significantly reducing the potential for human error and accelerating result turnaround times. By automating intricate imaging tasks, AI streamlines the clinical diagnostic process, thereby enhancing accessibility and cost-effectiveness in imaging solutions. This technological evolution not only facilitates quicker and more reliable data interpretations but also supports clinical decision-making, reflecting a growing reliance on advanced imaging technologies to optimize clinical trial outcomes.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Ecosystem of the Market
Patent Analysis
Pricing Analysis
Trade Analysis
Value Chain Analysis
Supply Chain Analysis
Customer & Buying Criteria Analysis
Case Study Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Clinical Trial Imaging Market by Service and Software

Market Overview
Services
- Operational Imaging Services
- Read Analysis Services
- System & Technical Support Services
- Trial Design & Consulting Services
Software

Clinical Trial Imaging Market by Modality

Market Overview
Computed Tomography
Magnetic Resonance Imaging
Ultrasound
Positron Emission Tomography
X-Ray
Others

Clinical Trial Imaging Market by Therapeutic Area

Market Overview
Oncology
Infectious Diseases
Neurology
Cardiovascular System Disorders
Endocrinology
Immunological Disorders
Others

Clinical Trial Imaging Market by End User

Market Overview
Pharmaceutical & Biotechnology Companies
Medical Device Manufacturers
Contract Research Organizations
Academic And Government Research Institutes
Others

Clinical Trial Imaging Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

ICON plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medpace
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Clario
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IXICO plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Resonance Health Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Radiant Sage
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WCG Clinical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medical Metrics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Prism Clinical Imaging
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boston Imaging Core Lab
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Voiant
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Calyx
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biospective Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Micron, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Imaging Endpoints
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Perspectum
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Competence Network Life Sciences (Pharmtrace)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Median Technologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Image Core Lab
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Image Analysis Group (IAG)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments